Graeme N. Forrest
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Graeme N. Forrest has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Elizabeth Weekes
2 shared publicationsJennifer K. Johnson
2 shared publicationsK. Mankes
Division of Infectious Diseases, University of Maryland School of Medicine, Baltimore, Maryland, USA
2 shared publicationsAlan Cross
University of Maryland Medical Center and School of Medicine, Department of Medicine, Division of Infectious Diseases, Baltimore, Maryland, USA
1 shared publicationD. P. Lincalis
University of Maryland School of Medicine, Division of Infectious Diseases, Baltimore, Maryland 21201,1 University of Maryland School of Dentistry, Baltimore, Maryland 21201,2 University of Maryland Medical Center, Department of Pharmacy, Baltimore, Maryland 21201,3 University of Maryland School of Medicine, Department of Pathology, Baltimore, Maryland 212014
1 shared publicationDurry P. Lincalis
Department of Pathology, University of Maryland 22 South Greene Street, N2W50b, Baltimore, MD, USA
1 shared publication
Latest Publications
- 1 February 2008
- Published by Elsevier in Journal of Infection
- Vol. 56 (2) , 126-129
Increasing incidence of Candida parapsilosis candidemia with caspofungin usage
- 1 February 2008
- Published by Elsevier in Journal of Infection
- Vol. 56 (2) , 126-129
Increasing incidence of Candida parapsilosis candidemia with caspofungin usage
- 1 December 2007
- Published by Wolters Kluwer Health in Current Opinion in Organ Transplantation
- Vol. 12 (6) , 604-609
Is there a role for antimicrobial management in organ transplantation?
- 1 December 2007
- Published by Wolters Kluwer Health in Current Opinion in Organ Transplantation
- Vol. 12 (6) , 604-609
Is there a role for antimicrobial management in organ transplantation?
- 1 May 2007
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 7 (3) , 231-236
PNA FISH: present and future impact on patient management
Inappropriate and inaccurate antimicrobial therapy can lead to adverse patient outcomes and also the development of antimicrobial resistance. Peptide nucleic acid (PNA) fluorescence in situ hybridization (FISH) gives rapid reporting with highly sensitive and specific results to clinicians within 3 h after blood cultures turn positive, thereby offering targeted therapeutics where necessary. It is simple to establish compared with real-time PCR and has resulted in significant cost savings for hospitals. PNA FISH is a promising future technology for the microbiology laboratory that will impact on patient management and clinical guidelines. This article will review the clinical data supporting these new technologies.
- 1 May 2007
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 7 (3) , 231-236
PNA FISH: present and future impact on patient management
Inappropriate and inaccurate antimicrobial therapy can lead to adverse patient outcomes and also the development of antimicrobial resistance. Peptide nucleic acid (PNA) fluorescence in situ hybridization (FISH) gives rapid reporting with highly sensitive and specific results to clinicians within 3 h after blood cultures turn positive, thereby offering targeted therapeutics where necessary. It is simple to establish compared with real-time PCR and has resulted in significant cost savings for hospitals. PNA FISH is a promising future technology for the microbiology laboratory that will impact on patient management and clinical guidelines. This article will review the clinical data supporting these new technologies.
- 30 January 2007
- Published by Wiley in Transplant Infectious Disease
- Vol. 9 (2) , 161-164
Outcomes of invasive zygomycosis infections in renal transplant recipients
Zygomycosis is an infrequent and difficult‐to‐treat fungal infection that is found in patients with underlying immunocompromised states. The advent of the lipid amphotericin B products has allowed for treatment with higher doses of therapy and less systemic toxicity. We reviewed the outcomes of 6 renal transplant recipients diagnosed with biopsy‐proven invasive zygomycosis who received amphotericin B lipid complex (ABLC) in doses greater than 5 mg/kg between 2000 and 2004. All 6 patients had baseline diabetes mellitus, were receiving immunosuppressive agents, and subsequently underwent concomitant surgery. Three of the 6 patients that survived had undergone significant surgical debridement, reduction of their immunosuppression to minimal prednisone, and received prolonged course of ABLC at 10 mg/kg/day. All survivors lost graft function during the course of their therapy. The 3 patients who died all had delays in diagnosis of their disease and subsequent surgical and appropriate medical therapy. Therefore, in renal transplant recipients the early diagnosis of invasive zygomycosis is imperative along with early therapy with surgical debridement, reduced immunosuppression, and the use of high doses of ABLC.
- 30 January 2007
- Published by Wiley in Transplant Infectious Disease
- Vol. 9 (2) , 161-164
Outcomes of invasive zygomycosis infections in renal transplant recipients
Zygomycosis is an infrequent and difficult‐to‐treat fungal infection that is found in patients with underlying immunocompromised states. The advent of the lipid amphotericin B products has allowed for treatment with higher doses of therapy and less systemic toxicity. We reviewed the outcomes of 6 renal transplant recipients diagnosed with biopsy‐proven invasive zygomycosis who received amphotericin B lipid complex (ABLC) in doses greater than 5 mg/kg between 2000 and 2004. All 6 patients had baseline diabetes mellitus, were receiving immunosuppressive agents, and subsequently underwent concomitant surgery. Three of the 6 patients that survived had undergone significant surgical debridement, reduction of their immunosuppression to minimal prednisone, and received prolonged course of ABLC at 10 mg/kg/day. All survivors lost graft function during the course of their therapy. The 3 patients who died all had delays in diagnosis of their disease and subsequent surgical and appropriate medical therapy. Therefore, in renal transplant recipients the early diagnosis of invasive zygomycosis is imperative along with early therapy with surgical debridement, reduced immunosuppression, and the use of high doses of ABLC.
- 1 December 2006
- Published by Wolters Kluwer Health in Current Opinion in Infectious Diseases
- Vol. 19 (6) , 538-543
Role of antifungal susceptibility testing in patient management
The review focuses on the evolving role of antifungal susceptibility testing in the clinical management of patients with invasive fungal infections. It will clarify how to clinically interpret available susceptibility testing methods. Fluconazole susceptibility testing for yeasts has now shown a relationship between fluconazole resistance and therapeutic failure. Of increasing concern are the reported cases of fluconazole cross-resistance to the newer triazoles. The correlation between amphotericin B and echinocandin susceptibility testing for yeasts, resistance, and outcomes is unknown. Although there are reports of clinical failures with echinocandins, resistance is uncommon and susceptibility testing is unhelpful. There are standardized methods of testing for the triazoles and amphotericin B against molds; however, resistance has not been correlated with outcomes due to host and laboratory factors. Knowing the intrinsic resistance of molds to particular antifungals is of greater importance. Posaconazole is a potent new antifungal agent against many difficult-to-treat molds including fusariosis and zygomycosis. Antifungal susceptibility testing of yeasts can assist in treating patients with prior antifungal exposure in determining resistance or cross-resistance. Mold susceptibility testing is of limited clinical benefit, while posconazole is an exciting new agent for treating difficult invasive fungal infections.
- 1 December 2006
- Published by Wolters Kluwer Health in Current Opinion in Infectious Diseases
- Vol. 19 (6) , 538-543
Role of antifungal susceptibility testing in patient management
The review focuses on the evolving role of antifungal susceptibility testing in the clinical management of patients with invasive fungal infections. It will clarify how to clinically interpret available susceptibility testing methods. Fluconazole susceptibility testing for yeasts has now shown a relationship between fluconazole resistance and therapeutic failure. Of increasing concern are the reported cases of fluconazole cross-resistance to the newer triazoles. The correlation between amphotericin B and echinocandin susceptibility testing for yeasts, resistance, and outcomes is unknown. Although there are reports of clinical failures with echinocandins, resistance is uncommon and susceptibility testing is unhelpful. There are standardized methods of testing for the triazoles and amphotericin B against molds; however, resistance has not been correlated with outcomes due to host and laboratory factors. Knowing the intrinsic resistance of molds to particular antifungals is of greater importance. Posaconazole is a potent new antifungal agent against many difficult-to-treat molds including fusariosis and zygomycosis. Antifungal susceptibility testing of yeasts can assist in treating patients with prior antifungal exposure in determining resistance or cross-resistance. Mold susceptibility testing is of limited clinical benefit, while posconazole is an exciting new agent for treating difficult invasive fungal infections.
- Open Access
- 1 September 2006
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 44 (9) , 3381-3383
Peptide Nucleic Acid Fluorescence In Situ Hybridization-Based Identification of Candida albicans and Its Impact on Mortality and Antifungal Therapy Costs
The impact of rapid identification of Candida albicans blood isolates by peptide nucleic acid fluorescence in situ hybridization (PNA FISH) on the selection and expenditure of antifungal therapy was evaluated. PNA FISH was 100% sensitive and specific in the rapid identification of 31 out of 72 candidemias as C. albicans and resulted in a significant reduction of caspofungin usage, with an overall cost savings of $1,729 per patient.
- 1 September 2006
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 44 (9) , 3381-3383
Open AccessPeptide Nucleic Acid Fluorescence In Situ Hybridization-Based Identification of Candida albicans and Its Impact on Mortality and Antifungal Therapy Costs
The impact of rapid identification of Candida albicans blood isolates by peptide nucleic acid fluorescence in situ hybridization (PNA FISH) on the selection and expenditure of antifungal therapy was evaluated. PNA FISH was 100% sensitive and specific in the rapid identification of 31 out of 72 candidemias as C. albicans and resulted in a significant reduction of caspofungin usage, with an overall cost savings of $1,729 per patient.
- Open Access
- 24 April 2006
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 58 (1) , 154-158
Impact of rapid in situ hybridization testing on coagulase-negative staphylococci positive blood cultures
Objectives: To evaluate the impact of the rapid differentiation of Staphylococcus aureus from coagulase-negative staphylococci (CoNS) in blood cultures using peptide nucleic acid fluorescence in situ hybridization (PNA FISH) on vancomycin usage, length of patient hospital stay and hospital costs. Design: This was a retrospective, cost-effective analysis of PNA FISH in its initial 3 month implementation period in 2004 in a 650 bed academic medical centre. Blood cultures with Gram-positive cocci in clusters (GPCC) that were negative for S. aureus using the PNA FISH assay were compared with an untested control group in the same period that had similar illness severity and location. We evaluated the effectiveness of the early identification of CoNS by ruling out S. aureus in conjunction with an antimicrobial team (AMT) on antimicrobial therapy, patient length of stay and hospital costs. Results: A total of 139 blood cultures positive with GPCC had PNA FISH results while 84 in the control group did not. Evaluable criteria were met in 53 patients in the PNA FISH group and 34 in the control group. When comparing the results obtained from using the PNA FISH assay with those for the control group, there was a significant reduction in median length of hospital stay from 6 to 4 days (P < 0.05, CI 0.95–1.87) and a trend towards less vancomycin usage with a decrease in associated hospital costs of ∼$4000 per patient. Conclusions: The PNA FISH assay is rapid, accurate and reliable and in association with an AMT could decrease hospital length of stay in patients with CoNS bacteraemia in non-intensive care unit settings and prevent excessive vancomycin usage.
- 24 April 2006
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 58 (1) , 154-158
Open AccessImpact of rapid in situ hybridization testing on coagulase-negative staphylococci positive blood cultures
Objectives: To evaluate the impact of the rapid differentiation of Staphylococcus aureus from coagulase-negative staphylococci (CoNS) in blood cultures using peptide nucleic acid fluorescence in situ hybridization (PNA FISH) on vancomycin usage, length of patient hospital stay and hospital costs. Design: This was a retrospective, cost-effective analysis of PNA FISH in its initial 3 month implementation period in 2004 in a 650 bed academic medical centre. Blood cultures with Gram-positive cocci in clusters (GPCC) that were negative for S. aureus using the PNA FISH assay were compared with an untested control group in the same period that had similar illness severity and location. We evaluated the effectiveness of the early identification of CoNS by ruling out S. aureus in conjunction with an antimicrobial team (AMT) on antimicrobial therapy, patient length of stay and hospital costs. Results: A total of 139 blood cultures positive with GPCC had PNA FISH results while 84 in the control group did not. Evaluable criteria were met in 53 patients in the PNA FISH group and 34 in the control group. When comparing the results obtained from using the PNA FISH assay with those for the control group, there was a significant reduction in median length of hospital stay from 6 to 4 days (P < 0.05, CI 0.95–1.87) and a trend towards less vancomycin usage with a decrease in associated hospital costs of ∼$4000 per patient. Conclusions: The PNA FISH assay is rapid, accurate and reliable and in association with an AMT could decrease hospital length of stay in patients with CoNS bacteraemia in non-intensive care unit settings and prevent excessive vancomycin usage.
- Open Access
- 15 January 2005
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 40 (2) , 313-314
A Liver Transplant Recipient with an Infected Explanted Liver
- 15 January 2005
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 40 (2) , 313-314
Open AccessA Liver Transplant Recipient with an Infected Explanted Liver
- 1 January 2004
- Published by Wolters Kluwer Health in Current Opinion in Gastroenterology
- Vol. 20 (1) , 16-21
Gastrointestinal infections in immunocompromised hosts
Purpose of review Patients with immunocompromised states are increasing in the world not only because of HIV infection but also as a result of better therapies in solid organ transplantation, stem cell transplantation, and leukemia. All these patients are at similar risk of gastrointestinal infections, and the subsequent morbidity and mortality from these infections makes it important to recognize the net state of immunosuppression of each person infected. Recent findings This review evaluates emerging pathogens, new diagnostic tools and guidelines, and the latest therapies published in the last 12 months in HIV and solid organ transplantation. The echinocandins provide a new therapy for Candida esophagitis, whereas Mycobacterium avium complex therapy may be discontinued with immune reconstitution in patients with HIV. The emergence of antimicrobial-resistant bacteria and viruses is a new threat to managing these infections, especially in poorer countries. Also, several community viruses such as adenovirus were shown to cause significant morbidity to immunocompromised patients. Lastly, the interaction among immunosuppressive medications, diarrhea, and rejection makes an important argument for evaluating patients for infection before adjusting medications. Summary The immunocompromised host is rapidly increasing in the world, resulting in exposures to new pathogenic organisms that cause gastrointestinal infections. New diagnostic tests and better antimicrobial therapy are improving outcomes in patients with access to health care. Unfortunately, these challenges are increasing daily with the development of multidrug-resistant bacteria and viruses that do not respond to standard therapies. The most important factor in overcoming these infections is restoration of the immune system, either by using antiretroviral therapy or decreasing immunosuppression.
- 1 January 2004
- Published by Wolters Kluwer Health in Current Opinion in Gastroenterology
- Vol. 20 (1) , 16-21
Gastrointestinal infections in immunocompromised hosts
Purpose of review Patients with immunocompromised states are increasing in the world not only because of HIV infection but also as a result of better therapies in solid organ transplantation, stem cell transplantation, and leukemia. All these patients are at similar risk of gastrointestinal infections, and the subsequent morbidity and mortality from these infections makes it important to recognize the net state of immunosuppression of each person infected. Recent findings This review evaluates emerging pathogens, new diagnostic tools and guidelines, and the latest therapies published in the last 12 months in HIV and solid organ transplantation. The echinocandins provide a new therapy for Candida esophagitis, whereas Mycobacterium avium complex therapy may be discontinued with immune reconstitution in patients with HIV. The emergence of antimicrobial-resistant bacteria and viruses is a new threat to managing these infections, especially in poorer countries. Also, several community viruses such as adenovirus were shown to cause significant morbidity to immunocompromised patients. Lastly, the interaction among immunosuppressive medications, diarrhea, and rejection makes an important argument for evaluating patients for infection before adjusting medications. Summary The immunocompromised host is rapidly increasing in the world, resulting in exposures to new pathogenic organisms that cause gastrointestinal infections. New diagnostic tests and better antimicrobial therapy are improving outcomes in patients with access to health care. Unfortunately, these challenges are increasing daily with the development of multidrug-resistant bacteria and viruses that do not respond to standard therapies. The most important factor in overcoming these infections is restoration of the immune system, either by using antiretroviral therapy or decreasing immunosuppression.
- 1 April 2002
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 10 (3) , 177-180
Febrile neutropenia, colony-stimulating factors and therapy: time for a new methodology?
The utilization of granulocyte colony-stimulating factors (G-CSF) in febrile neutropenia has been controversial for many years. Berghmann et al.’s meta-analysis again demonstrates that G-CSF does not have an impact on mortality in febrile neutropenia, because the depth and duration of neutropenia in the trials are variable. Also, with mortality from febrile neutropenia less than 15%, any further study would require a vast number of patients to demonstrate a difference in mortality. The Elting and Cantor review provides a new paradigm to studies in patients with febrile neutropenia. These authors recognize that cost, quality of life, life-years gained and adverse events experienced with new therapies should be evaluated, in addition to the standard measures of infection resolution and related mortality. Therefore, for the evaluation of new therapeutic interventions, a consensus on stratified risk factors or the use of an already established model could provide end-points with comparable measurements.
- 1 April 2002
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 10 (3) , 177-180
Febrile neutropenia, colony-stimulating factors and therapy: time for a new methodology?
The utilization of granulocyte colony-stimulating factors (G-CSF) in febrile neutropenia has been controversial for many years. Berghmann et al.’s meta-analysis again demonstrates that G-CSF does not have an impact on mortality in febrile neutropenia, because the depth and duration of neutropenia in the trials are variable. Also, with mortality from febrile neutropenia less than 15%, any further study would require a vast number of patients to demonstrate a difference in mortality. The Elting and Cantor review provides a new paradigm to studies in patients with febrile neutropenia. These authors recognize that cost, quality of life, life-years gained and adverse events experienced with new therapies should be evaluated, in addition to the standard measures of infection resolution and related mortality. Therefore, for the evaluation of new therapeutic interventions, a consensus on stratified risk factors or the use of an already established model could provide end-points with comparable measurements.